Effects of celecoxib on high-sensitivity C-reactive protein in chronic peritoneal dialysis patients

Renal Failure

Volumn 26, Issue 4, 2004, Pages 381-384

  Kim, Soon Bae ^a,b   Kim, Sang Hyun ^a,b   Chang, Jae Won ^a,b   Lee, Sang Koo ^a,b   Min, Won Ki ^a,b   Chi, Hyun Sook ^a,b   Park, Jung Sik ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

C reactive protein; Celecoxib; Peritoneal dialysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; D DIMER; HIGH SENSITIVITY C REACTIVE PROTEIN; TROPONIN T; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; LONG TERM CARE; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-REACTIVE PROTEIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; PYRAZOLES; SULFONAMIDES; TROPONIN T; VON WILLEBRAND FACTOR;

EID: 4444351117     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120039821     Document Type: Article

References (10)

1. Ross, R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999, 340 (2), 115-126.
2. American Society of Health-System Pharmacists. In AHFS Drug Information, 42th Ed.; American Society of Health-System Pharmacists: Bethesda, MD, 2000; 1872-1879.
3. Chenevard, R.; Hurlimann, D.; Bechir, M.; Enseleit, F.; Spieker, L.; Hermann, M.; Riesen, W.; Gay, S.; Gay, R.E.; Neidhart, M.; Michel, B.; Luscher, T.F.; Noll, G.; Ruschitzka, F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107 (3), 405-409.
4. Casolini, P.; Catalani, A.; Zuena, A.R.; Angelucci, L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J. Neurosci. Res. 2002, 68 (3), 337-343.
5. Lip, G.Y.H.; Lowe, G.D.O.; Rumley, A.; Dunn, F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br. Heart J. 1995, 73 (6), 527-533.
6. Takagi, M.; Wada, H.; Mukai, K.; Kihira, H.; Yano, S.; Minamikawa, K.; Wakita, Y.; Nakase, T.; Nagaya, S.; Deguchi, K. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance hemodialysis. Blood Coagul. Fibrinolysis 1994, 5 (5), 713-717.
7. de Winter, R.J. C-reactive protein and cardiac troponin for early risk stratification in patients with acute coronary syndromes. Clin. Chim. Acta 2001, 311 (1), 53-56.
8. Kim, S.B.; Lee, S.K.; Min, W.K.; Chi, H.S.; Park, J.S. Lack of effects of low-dose aspirin on high-sensitivity C-reactive protein, hemostatic factors, and troponin T in CAPD patients. Perit. Dial. Int. 2003, 22 (6), 721-723.
9. Crofford, L.J.; Lipsky, P.E.; Brooks, P.; Abramson, S.B.; Simon, L.S.; Van de Putte, L.B.A. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 2000, 43 (1), 4-13.
10. White, W.B.; Faich, G.; Whelton, A.; Maurath, C.; Ridge, N.J.; Verburg, K.M.; Geis, G.S.; Lefkowith, J.B. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol. 2002, 89 (4), 425-430.